Good afternoon, –
Today, Thermo Fisher Scientific has introduced the Ion Torrent Oncomine Myeloid Assay GX v2, which is the is the first NGS assay for myeloid samples that provides results in a single day using the Genexus System.
Myeloid cancers present unique challenges due to their heterogeneity and sample complexity. As the list of myeloid biomarkers continues to grow, rapid and streamlined solutions are needed to analyze complex and heterogeneous myeloid malignancy samples. The expanded panel profiles key biomarkers for all major myeloid disorders, enabling simultaneous profiling of 45 genes (DNA) and 30 fusion drivers (RNA) covering more than 700 unique fusions.
For your product/news coverage, a full brief detailing the key functionality of the new assays is included below. Please let me know if you would like any additional information.
Have a nice day,
Georgia
--
CARLSBAD, Calif., December 10, 2021 –Oncomine Myeloid Assay GX v2 Provides Comprehensive, Rapid Molecular Profiling of Myeloid Samples
| Overview: | The Ion Torrent Oncomine Myeloid Assay GX v2* from Thermo Fisher Scientific is the first next-generation sequencing (NGS) assay that allows researchers to gather comprehensive mutational results from myeloid samples in a single day using the Ion Torrent Genexus System.*
As the list of myeloid biomarkers continues to grow, rapid and streamlined solutions are needed to analyze complex and heterogeneous myeloid malignancy samples. The Oncomine Myeloid Assay GX v2 offers a comprehensive panel to profile key biomarkers for all major myeloid disorders with minimal hands-on time.
The assay is optimized to reliably detect a wide range of variants, including challenging-to-sequence targets such as FLT3-ITD, CALR and CEBPA. The updates for this version include additional DNA and RNA targets, improved sequencing of key GC-rich regions, the ability to run the RNA and DNA panels separately, and is available on the Genexus System for an optimized, rapid specimen-to-report workflow.
| | Key Applications: | Oncology research on myeloid disorders including acute myeloid leukemia (AML), myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDS).
| | Features/Benefits: | - Rapid turnaround: Runs on the Genexus System, which integrates nucleic acid purification and quantification**, library preparation, sequencing and analysis to provide comprehensive reports in a single day, compared to multiple weeks with other workflows.
- Automated workflow: Enables samples to be processed from specimen to report with only 20 minutes of hands-on time for technicians and minimal user intervention.
- Broad target coverage: An expanded panel enables simultaneous profiling of 45 genes (DNA) and 30 fusion drivers (RNA) covering more than 700 unique fusions.
- Full specimen coverage: Analyzes all common specimen types relevant for myeloid disorders, including whole blood, peripheral blood lymphocytes (PBLs) and bone marrow.
- Integrated reporting: Provides annotated variant reports, including links to the latest relevant evidence from public data sources.
|
Web Site: |
www.oncomine.com/myeloid
| | | |
| |
|---|
*For Research Use Only. Not for use in diagnostic procedures.
**The specimen-to-report workflow will be available for RNA samples once the Total RNA Purification Kits are available in approximately early 2022.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team of more than 100,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.